Physician profile
Mark E Boschert
NPI 1346252236
$1,187.86
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $61.26 · 2021: $142 · 2022: $242 · 2023: $255 · 2024: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.78 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $279.13 | 2022-2024 | Stelara |
| Pfizer INC. | $198.46 | 2019-2024 | |
| Gilead Sciences, INC. | $118.22 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.63 | 2019-2024 | Entyvio |
| Abbvie INC. | $107.81 | 2019-2023 | Skyrizi, Rinvoq |
| Organon LLC | $79.21 | 2021-2024 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $70.53 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $37.90 | 2019-2020 | |
| Allergan, INC. | $32.31 | 2019 | |
| Tepha INC | $31.78 | 2019 | |
| Pharming Healthcare, INC. | $26.34 | 2023 | Ruconest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.06 | 2019-2020 | |
| Braintree Laboratories, INC. | $20.07 | 2022 | |
| Qol Medical, LLC | $17.90 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.37 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $14.14 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,973.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Boschert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.